Bobby J. Lucas
About
Bobby J. Lucas is a scholar working on Organic Chemistry, Molecular Biology and Hematology.
According to data from OpenAlex, Bobby J. Lucas has authored 21 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Organic Chemistry, 10 papers in Molecular Biology and 8 papers in Hematology. Recurrent topics in Bobby J. Lucas's work include Chemical Synthesis and Analysis (10 papers), Blood Coagulation and Thrombosis Mechanisms (8 papers) and Peptidase Inhibition and Analysis (6 papers). Bobby J. Lucas is often cited by papers focused on Chemical Synthesis and Analysis (10 papers), Blood Coagulation and Thrombosis Mechanisms (8 papers) and Peptidase Inhibition and Analysis (6 papers). Bobby J. Lucas collaborates with scholars based in United States and United Kingdom. Bobby J. Lucas's co-authors include Sidney D. Lewis, Joseph P. Vacca, Adel M. Naylor-Olsen, Julie A. Krueger, Elizabeth A. Lyle, Joseph J. Lynch, William C. Lumma, Thomas J. Tucker, Philip E.J. Sanderson and Youwei Yan and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and Bioorganic & Medicinal Chemistry.
In The Last Decade
Bobby J. Lucas
21 papers receiving 485 citations
Peers
Bobby J. Lucas
Adel M. Naylor-Olsen United States
John M. Fevig United States
Julie A. Krueger United States
Kurt Hilpert Switzerland
Jörg Hauptmann Germany
Michael D. Boisclair United States
Satoshi Komoriya Japan
Noriyasu Haginoya Japan
Lori L. Bostrom United States
Michael J. Orwat United States
Citations per year, relative to Bobby J. Lucas Bobby J. Lucas (= 1×)
peers
Adel M. Naylor-Olsen
Countries citing papers authored by Bobby J. Lucas
Since
Specialization
Citations
This map shows the geographic impact of Bobby J. Lucas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bobby J. Lucas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bobby J. Lucas more than expected).
Fields of papers citing papers by Bobby J. Lucas
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bobby J. Lucas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bobby J. Lucas. The network helps show where Bobby J. Lucas may publish in the future.
Co-authorship network of co-authors of Bobby J. Lucas
This figure shows the co-authorship network connecting the top 25 collaborators of Bobby J. Lucas. A scholar is included among the top collaborators of Bobby J. Lucas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bobby J. Lucas. Bobby J. Lucas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Isaacs, Richard C.A., Swati P. Mercer, Bruce D. Dorsey, et al.. (2010). P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position. Bioorganic & Medicinal Chemistry Letters. 21(5). 1532–1535.
2.
Isaacs, Richard C.A., Swati P. Mercer, Linda S. Payne, et al.. (2010). Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(5). 1536–1540.
3.
Isaacs, Richard C.A., Adel M. Naylor-Olsen, Daniel R. McMasters, et al.. (2008). Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles. Bioorganic & Medicinal Chemistry Letters. 18(6). 2062–2066.
4.
Lyle, Terry A., Daniel R. McMasters, Philip E.J. Sanderson, et al.. (2006). Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability. Bioorganic & Medicinal Chemistry. 14(20). 6900–6916.
5.
Deng, James Z., Daniel R. McMasters, Peter Williams, et al.. (2005). Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization. Bioorganic & Medicinal Chemistry Letters. 15(20). 4411–4416.
6.
Isaacs, Richard C.A., et al.. (2005). Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 1: Weakly basic azoles. Bioorganic & Medicinal Chemistry Letters. 16(2). 338–342.
7.
Stauffer, Kenneth J., Peter Williams, Terry A. Lyle, et al.. (2004). Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability. Bioorganic & Medicinal Chemistry Letters. 14(16). 4161–4164.
8.
Sanderson, Philip E.J., Matthew G. Stanton, Bruce D. Dorsey, et al.. (2003). Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(5). 795–798.
9.
Rittle, Kenneth E., James C. Barrow, Julie A. Krueger, et al.. (2003). Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position. Bioorganic & Medicinal Chemistry Letters. 13(20). 3477–3482.
10.
Sanderson, Philip E.J., Adel M. Naylor-Olsen, Franklin C. Clayton, et al.. (2003). 3-Amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(8). 1441–1444.
11.
Nantermet, Philippe G., James C. Barrow, Sidney D. Lewis, et al.. (2003). Design and synthesis of potent and selective macrocyclic thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(16). 2781–2784.
12.
Sanderson, Philip E.J., Julie A. Krueger, Lawrence C. Kuo, et al.. (2003). Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the ‘Distal binding pocket’. Bioorganic & Medicinal Chemistry Letters. 13(2). 161–164.
13.
Coburn, Craig A., Peter Williams, Carl F. Homnick, et al.. (2000). Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(10). 1069–1072.
14.
Lumma, William C., Keith M. Witherup, Thomas J. Tucker, et al.. (1998). Design of Novel, Potent, Noncovalent Inhibitors of Thrombin with Nonbasic P-1 Substructures: Rapid Structure−Activity Studies by Solid-Phase Synthesis. Journal of Medicinal Chemistry. 41(7). 1011–1013.
15.
Lewis, Sidney D., Bobby J. Lucas, Stephen F. Brady, et al.. (1998). Characterization of the Two-step Pathway for Inhibition of Thrombin by α-Ketoamide Transition State Analogs. Journal of Biological Chemistry. 273(9). 4843–4854.
16.
Sanderson, Philip E.J., Bruce D. Dorsey, Colleen M. McDonough, et al.. (1998). L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorganic & Medicinal Chemistry Letters. 8(7). 817–822.
17.
Brady, Stephen F., Kenneth J. Stauffer, William C. Lumma, et al.. (1998). Discovery and Development of the Novel Potent Orally Active Thrombin Inhibitor N-(9-Hydroxy-9-fluorenecarboxy)prolyl trans-4-Aminocyclohexylmethyl Amide (L-372,460): Coapplication of Structure-Based Design and Rapid Multiple Analogue Synthesis on Solid Support. Journal of Medicinal Chemistry. 41(3). 401–406.
18.
Sanderson, Philip E.J., Adel M. Naylor-Olsen, Joseph P. Vacca, et al.. (1997). L-373,890, An achiral, noncovalent, subnanomolar thrombin inhibitor. Bioorganic & Medicinal Chemistry Letters. 7(12). 1497–1500.
19.
Tucker, Thomas J., William C. Lumma, Sidney D. Lewis, et al.. (1997). Potent Noncovalent Thrombin Inhibitors That Utilize the Unique Amino Acid d -Dicyclohexylalanine in the P3 Position. Implications on Oral Bioavailability and Antithrombotic Efficacy. Journal of Medicinal Chemistry. 40(11). 1565–1569.
20.
Tucker, Thomas J., William C. Lumma, Sidney D. Lewis, et al.. (1997). Synthesis of a Series of Potent and Orally Bioavailable Thrombin Inhibitors That Utilize 3,3-Disubstituted Propionic Acid Derivatives in the P3 Position. Journal of Medicinal Chemistry. 40(22). 3687–3693.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Adel M. Naylor-Olsen Breakdown of academic impact, for papers by John M. Fevig Breakdown of academic impact, for papers by Julie A. Krueger Breakdown of academic impact, for papers by Kurt Hilpert Breakdown of academic impact, for papers by Jörg Hauptmann Breakdown of academic impact, for papers by Michael D. Boisclair Breakdown of academic impact, for papers by Satoshi Komoriya Breakdown of academic impact, for papers by Noriyasu Haginoya Breakdown of academic impact, for papers by Lori L. Bostrom Breakdown of academic impact, for papers by Michael J. Orwat